# Emcure Pharmaceuticals delivered a strong performance in Q4 and full-year FY26, crossing the US$1 billion revenue milestone.

*biotech · news · 2026-05-06 · scanx.trade*

## Key points

- Emcure Pharmaceuticals crossed US$1 billion in revenue, growing 16.6% year-on-year to ₹9,204 Cr.
- International business drove growth, with Europe revenue up 35.8% YoY and Canada up 28.6%.
- R&D investment rose to ₹384 Cr in FY26, 4.2% of revenue, up from ₹287 Cr in FY25.
- Net debt increased to ₹1,054 Cr due to Zuventus consolidation and Manx acquisition.
- Emcure formed new partnerships with Novo Nordisk, Sanofi, and Roche for portfolio expansion.

**Companies:** Emcure Pharmaceuticals
**Countries:** India, UK, Canada, Singapore, Brazil

[Read the full story on scanx.trade](https://scanx.trade/stock-market-news/companies/emcure-pharmaceuticals-reports-strong-q4-performance-with-revenue-at-24-7b-rupees-and-improved-ebitda-margins/39557635)

---

Canonical: https://newsio.io/n/9f9f9a4d-d8f9-49cb-8003-60a43919b07a/emcure-pharmaceuticals-delivered-a-strong-performance-in-q4-and-full-year-fy26-c
Summarized by Newsio from scanx.trade. https://newsio.io/how-it-works